EyePoint Pharmaceuticals, Inc. (EYPT), a clinical-stage biopharmaceutical company, on Wednesday announced positive six-month results from its ongoing Phase 2 VERONA trial.
The VERONA trial is a randomized, controlled, Phase 2 study evaluating the efficacy and safety of DURAVYU in patients with diabetic macular edema (DME) who have previously been treated with anti-VEGF therapy.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com